Author, as appears in the article.: Perez-Calahorra S, Laclaustra M, Marco-Benedí V, Lamiquiz-Moneo I, Pedro-Botet J, Plana N, Sanchez-Hernandez RM, Amor AJ, Almagro F, Fuentes F, Suarez-Tembra M, Civeira F, Dyslipemia Registry of Spanish Arteriosclerosis Society

Department: Medicina i Cirurgia

URV's Author/s: Plana Gil, Núria

Keywords: Statins Risk Mutation Mortality Management Lipid-lowering Guidelines Guidance Familial hypercholesterolemia Diagnosis Coronary-heart-disease Cholesterol Cardiovascular disease Association lipid-lowering familial hypercholesterolemia cardiovascular disease

Abstract: The impact on heterozygous familial hypercholesterolemia (HeFH) health led by high-intensity lipid-lowering therapy (HILLT) is unknown, and the question remains if there is still an unacceptably high residual risk to justify treatment with new lipid-lowering drugs.This observational, retrospective, multicenter, national study in Spain, whose information was obtained from a national dyslipemia registry, was designed to establish the current prevalence of cardiovascular disease (CVD) in HeFH and to define the impact of HILLT on CVD in this population. Odds were estimated using several logistic regression models with progressive adjustment.1958 HeFH, mean age 49.3?±?14.3 years, were included in the analysis. At inclusion in the registry, 295 patients (15.1%) had suffered CVD and 164 (55.6%) had suffered the first event before the onset lipid-lowering treatment. Exposition to treatment associated more than ten times lower odds for CVD than in subjects naïve to treatment (OR 0.085, 95% CI 0.063-0.114, p?<?0.001). A first CVD event after a mean treatment period of 9.1?±?7.2 years occurred in 131 out of 1615 (8.1%) HeFH subjects, and 115 (87.8%) of them were on HILLT.Current prevalence of CVD among HeFH is one third of that reported before the statins era. Early initiation and prolonged lipid-lowering treatment was associated with a reduction in CVD. New cases of CVD, in spite of HILLT, appeared mostly among patients accumulating risk factors and probably they may be considered for further lipid-lowering drugs.Copyright © 2019 Elsevier B.V. All rights reserved.

Thematic Areas: Saúde coletiva Psicología Peripheral vascular disease Odontología Nutrição Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Engenharias ii Enfermagem Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Ciência da computação Cardiology and cardiovascular medicine Cardiac & cardiovascular systems Biotecnología Antropologia / arqueologia

licence for use: https://creativecommons.org/licenses/by/3.0/es/

ISSN: 00219150

Author's mail: nuria.plana@urv.cat

Author identifier: 0000-0002-4231-7618

Record's date: 2023-02-18

Papper version: info:eu-repo/semantics/acceptedVersion

Link to the original source: https://www.atherosclerosis-journal.com/article/S0021-9150(19)30081-4/fulltext

Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/

Papper original source: Atherosclerosis. 284 245-252

APA: Perez-Calahorra S, Laclaustra M, Marco-Benedí V, Lamiquiz-Moneo I, Pedro-Botet J, Plana N, Sanchez-Hernandez RM, Amor AJ, Almagro F, Fuentes F, Suarez (2019). Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. Atherosclerosis, 284(), 245-252. DOI: 10.1016/j.atherosclerosis.2019.02.003

Article's DOI: 10.1016/j.atherosclerosis.2019.02.003

Entity: Universitat Rovira i Virgili

Journal publication year: 2019

Publication Type: Journal Publications